BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11092616)

  • 1. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor.
    Wallace PK; Romet-Lemonne JL; Chokri M; Kasper LH; Fanger MW; Fadul CE
    Cancer Immunol Immunother; 2000 Nov; 49(9):493-503. PubMed ID: 11092616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.
    Wallace PK; Kaufman PA; Lewis LD; Keler T; Givan AL; Fisher JL; Waugh MG; Wahner AE; Guyre PM; Fanger MW; Ernstoff MS
    J Immunol Methods; 2001 Feb; 248(1-2):167-82. PubMed ID: 11223077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
    Chen J; Zhou JH; Ball ED
    Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of phagocytic MAK and MAC-DC for therapeutic use: characterization and in vitro functional properties.
    Boyer A; Andreu G; Romet-Lemonne JL; Fridman WH; Teillaud JL
    Exp Hematol; 1999 Apr; 27(4):751-61. PubMed ID: 10210333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma.
    Ely P; Wallace PK; Givan AL; Graziano RF; Guyre PM; Fanger MW
    Blood; 1996 May; 87(9):3813-21. PubMed ID: 8611707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of human macrophages with potent antitumor properties (MAK) by culture of monocytes in the presence of GM-CSF and 1,25-dihydroxy vitamin D3.
    Chokri M; Lopez M; Oleron C; Girard A; Martinache C; Canepa S; Siffert JC; Bartholeyns J
    Anticancer Res; 1992; 12(6B):2257-60. PubMed ID: 1295473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with CD64-directed immunotherapy. An overview.
    Curnow RT
    Cancer Immunol Immunother; 1997; 45(3-4):210-5. PubMed ID: 9435876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?
    Stadick H; Stockmeyer B; Kühn R; Schrott KM; Kalden JR; Glennie MJ; van de Winkel JG; Gramatzki M; Valerius T; Elsässer D
    J Urol; 2002 Feb; 167(2 Pt 1):707-12. PubMed ID: 11792958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human casein alpha s1 (CSN1S1) skews in vitro differentiation of monocytes towards macrophages.
    Vordenbäumen S; Braukmann A; Altendorfer I; Bleck E; Jose J; Schneider M
    BMC Immunol; 2013 Oct; 14():46. PubMed ID: 24083466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects.
    Faradji A; Bohbot A; Schmitt-Goguel M; Roeslin N; Dumont S; Wiesel ML; Lallot C; Eber M; Bartholeyns J; Poindron P
    Cancer Immunol Immunother; 1991; 33(5):319-26. PubMed ID: 1651160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
    Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
    MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
    Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
    J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro-differentiated human cell line as a model system to study the interaction of Neisseria gonorrhoeae with phagocytic cells.
    Hauck CR; Lorenzen D; Saas J; Meyer TF
    Infect Immun; 1997 May; 65(5):1863-9. PubMed ID: 9125573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated phenotype in neutrophils and monocytes from patients with primary proliferative polycythaemia.
    Westwood NB; Copson ER; Page LA; Mire-Sluis AR; Brown KA; Pearson TC
    J Clin Pathol; 1995 Jun; 48(6):525-30. PubMed ID: 7545186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.